Cormorant Asset Management, LP Crinetics Pharmaceuticals, Inc. Transaction History
Cormorant Asset Management, LP
- $1.27 Billion
- Q4 2024
A detailed history of Cormorant Asset Management, LP transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Cormorant Asset Management, LP holds 1,000,000 shares of CRNX stock, worth $35.1 Million. This represents 4.04% of its overall portfolio holdings.
Number of Shares
1,000,000
Previous 1,100,000
9.09%
Holding current value
$35.1 Million
Previous $56.2 Million
9.0%
% of portfolio
4.04%
Previous 3.94%
Shares
5 transactions
Others Institutions Holding CRNX
# of Institutions
254Shares Held
82.5MCall Options Held
26.1KPut Options Held
11.8K-
Vanguard Group Inc Valley Forge, PA9.09MShares$319 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.23MShares$218 Million0.01% of portfolio
-
Driehaus Capital Management LLC Chicago, IL6.14MShares$215 Million3.06% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.41MShares$190 Million0.03% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA4.29MShares$150 Million10.24% of portfolio
About Crinetics Pharmaceuticals, Inc.
- Ticker CRNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 53,752,800
- Market Cap $1.89B
- Description
- Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...